Estia Health share price on watch after coronavirus update

The Estia Health Ltd (ASX:EHE) share price will be on watch today after withdrawing its guidance due to the coronavirus outbreak…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Estia Health Ltd (ASX: EHE) share price could come under further pressure on Tuesday after it became the latest company to withdraw its guidance for FY 2020.

This follows moves by companies such as Cochlear Limited (ASX: COH) on Monday and Webjet Limited (ASX: WEB) last week that did the same.

a woman

What did Estia Health announce?

This morning Estia Health provided an update on current trading and its guidance for the full year.

According to the release, at this point, management notes that none of its homes have experienced cases of COVID-19 among residents or employees nor been materially impacted. As of March 15, the company's occupancy rate within its mature home portfolio was 93.8%.

However, due to the heightened uncertainty surrounding the potential future impact of coronavirus, the company is suspending its FY 2020 guidance.

The company notes that Australia is experiencing an unprecedented public health crisis of unknown dimensions with economic and financial implications that cannot at this point be estimated.

What now?

Management advised that it continues to monitor the COVID-19 situation closely and is planning for any further escalation.

Its focus is on the wellbeing and safety of staff and the frail and vulnerable residents and their families, while at the same time being responsive to the community need for access to residential aged care.

Management said: "At this stage it is not possible to have a high degree of certainty about the impact the situation may have on future occupancy, revenue and costs across the company's 69 homes. Given the dynamic and uncertain nature of this situation, it is not possible to provide meaningful guidance at this time on the size of the projected impact on earnings for the remainder of FY20."

The company notes that its disciplined capital management continues to be a key element of its strategy and its balance sheet strength is expected to give it greater flexibility and depth of resource to meet the challenges the crisis may present.

As of March 13, its net debt stood at ~$106 million, with undrawn and committed facilities under its Syndicated Financing Facility of ~$216 million. The net RAD balance on March 13 was ~$827 million, which includes amounts due under probate.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and Webjet Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.
Healthcare Shares

Up 60%: Why this exciting ASX stock could keep rising

This speculative stock could still have significant upside according to Bell Potter.

Read more »

A person holds their hands up through the middle of a rubber lifesaving ring while swimming in relatively calm conditions at a beach.
Healthcare Shares

Why this ASX healthcare high-flyer just dropped another 9% today

4DMedical shares are sliding again. Here’s what’s behind the drop.

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

Mayne Pharma stock jumps 8% on strong Q3 update. Has it finally bottomed?

Mayne Pharma's share price has rebounded 32% since hitting a five-year low in March.

Read more »

A young woman sits with her hand to her chin staring off to the side thinking about her investments.
Healthcare Shares

Down 65%, are Cochlear shares a once-in-a-decade buying opportunity?

After a brutal drop, sentiment has turned negative. But looking beyond the next year, the long-term story may still be…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

A big milestone for this ASX biotech. Here's why the share price is moving

Mesoblast hits a key trial milestone...

Read more »

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Healthcare Shares

Mesoblast shares in focus after key Phase 3 milestone for low back pain

Mesoblast shares are in focus after reaching a major patient recruitment milestone in its pivotal Phase 3 trial for chronic…

Read more »

CEO of a company talking.
Healthcare Shares

Regis Healthcare names Andrew Kinkade as new CEO

Regis Healthcare appoints Andrew Kinkade as CEO, unveiling new leadership strategy and key remuneration details.

Read more »

ASX share investor sitting with a laptop on a desk, pondering something.
Share Fallers

CSL shares crash to a 9-year low. Is it time to sell off my shares?

What's next for the beaten-down ASX biotech stock?

Read more »